Streetbeat News

Price Targets

ONCY

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Oncolytics Biotech (NASDAQ:ONCY) and maintained a $15 price target.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 2:29 pm

HRB

Barrington Research analyst Alexander Paris maintains an Outperform rating on H&R Block (NYSE:HRB) and raises the price target from $42 to $44.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 2:29 pm

HQI

Barrington Research analyst Kevin Steinke has maintained an 'Outperform' rating on HireQuest (NASDAQ:HQI), but lowered the price target from $29 to $26.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 2:28 pm

TLIS

BTIG analyst Mark Massaro maintains a 'Sell' rating on Talis Biomedical (NASDAQ:TLIS) and raises the price target from $0.35 to $5.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 2:27 pm

PAYS

Barrington Research analyst Gary Prestopino has reiterated an Outperform rating on PaySign (NASDAQ:PAYS) and maintained a price target of $5.5.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 2:26 pm

BBWI

Citigroup analyst Paul Lejuez has maintained a Neutral rating on Bath & Body Works (NYSE:BBWI) and raised the price target from $38 to $40.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 2:25 pm

AMZN

Amazon is raising the prices of its Amazon Music Unlimited plans for Prime members and family plan users. The price for Prime members will increase from $8.99 to $9.99 per month, and for family plan users from $15.99 to $16.99 per month. The new prices will be effective immediately for new customers and from September 19 for existing customers. This follows a trend of price hikes in music streaming services, with Spotify, Google's YouTube Music, and Apple Music also recently increasing their prices.

Portfolio Pulse from Happy Mohamed

August 16, 2023 | 2:23 pm

MMSI

Barrington Research analyst Michael Petusky has reiterated an 'Outperform' rating on Merit Medical Systems (NASDAQ:MMSI) and maintained a $95 price target.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 2:23 pm

SONN

Chardan Capital analyst Keay Nakae maintains a 'Buy' rating on Sonnet BioTherapeutics (NASDAQ:SONN) but has lowered the price target from $14 to $12.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 2:22 pm

TJX

Telsey Advisory Group has reiterated its 'Outperform' rating on TJX Companies and maintained its price target of $95.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 2:21 pm